Antibody Response
Conditions
Keywords
HIV, influenza, vaccination, MF-59
Brief summary
Until now, the adjuvanted influenza-related studies focused mainly on people at older ages. However, the data on immunocompromised people, who might have suboptimal serological responses when receiving nonadjuvanted vaccines, is scarce. In this study, we aim to compare the immunogenicity and safety to adjuvanted versus nonadjuvanted seasonal influenza vaccines among people with HIV.
Interventions
DRUGMF-59
MF-59 influenza vaccination
DRUGcell-based
cell-based influenza vaccination
DRUGegg-based
egg-based influenza vaccination
Sponsors
National Taiwan University Hospital, Cancer Center
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* People with HIV aged \> 50 years * Latest HIV RNA load tested less than 330 IU/mL
Exclusion criteria
* Confirmed serious adverse effect owing to any type of inluenza vaccine * severe coagulopathy * Have recieved influenza vaccine of 2025-2026 season
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SCR | between Day 1 and Day 28±7. | The primary end point includes SCR measured by the change in HI titer in serum against the vaccine strains between Day 1 and Day 28±7. |
Contacts
Primary ContactWang-Da Liu, M.D., M.P.H.
Outcome results
None listed